CDKN3 and liver cancer: Previous studies have found that ABCB6 (34), CDKN2A (35), CDKN3 (36), and TPI1 (37) (catalyzing the conversion of dihydroxyacetone phosphate (DHAP) and D-type glyceraldehyde 3-phosphate (G3P)), as well as HSPA8 (38), were potential targets for the treatment of liver cancer, which is consistent with our analysis results.